{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T07:07:09Z","timestamp":1775027229292,"version":"3.50.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Clin Rheumatol"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n            <jats:title>Background\/Objective<\/jats:title>\n            <jats:p>The Janus kinases (JAKs) are cytoplasmic tyrosine kinases associated with membrane cytokine receptors that mediate signaling of multiple cytokines and growth factors, contributing to the pathogenesis of multiple autoimmune disorders. The JAK inhibitors are a new class of targeted therapies with proven efficacy in treating rheumatoid arthritis but are associated with an increased risk of infections. This study is aimed at comparing the relative safety of the different JAK inhibitors with regard to the risk of serious infections in patients with rheumatoid arthritis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>PubMed, EMBASE, Cochrane Library, and clinicaltrials.gov were searched to identify randomized controlled trials evaluating the efficacy and safety of JAK inhibitors in patients with rheumatoid arthritis. The outcomes assessed were the risk of total and serious infections, tuberculosis, and herpes zoster. Sensitivity analysis disaggregated the results according to background therapy and licensed doses of JAK inhibitors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Thirty-seven randomized controlled trials that were included met the inclusion criteria. Compared with filgotinib, adalimumab (4.81; 95% confidence interval [CI], 1.39\u201316.66), etanercept (6.04; 95% CI, 1.79\u201320.37), peficitinib (7.56; 95% CI, 1.63\u201335.12), tofacitinib (4.29; 95% CI, 1.43\u201312.88), and upadacitinib (4.35; 95% CI, 1.46\u201313.00) have an increased risk of herpes zoster infection. Risk differences between the drugs became statistically nonsignificant when the sensitivity analysis was conducted.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The risk of infections seems to be similar among the currently approved JAK inhibitor drugs. Although the initial results suggested that filgotinib could have a reduced risk of herpes zoster, the sensitivity analyses did not support those findings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rhu.0000000000001749","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:07:03Z","timestamp":1619482023000},"page":"e407-e414","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":41,"title":["The Risk of Infections Associated With JAK Inhibitors in Rheumatoid Arthritis"],"prefix":"10.1097","volume":"28","author":[{"given":"Carlos","family":"Alves","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, University of Coimbra"}]},{"given":"Ana","family":"Penedones","sequence":"additional","affiliation":[{"name":"UFC\u2013Coimbra Regional Pharmacovigilance Unit, CHAD\u2013Centre for Health Technology Assessment and Drug Research, AIBILI\u2013Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal."}]},{"given":"Diogo","family":"Mendes","sequence":"additional","affiliation":[{"name":"UFC\u2013Coimbra Regional Pharmacovigilance Unit, CHAD\u2013Centre for Health Technology Assessment and Drug Research, AIBILI\u2013Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal."}]},{"given":"Francisco Batel","family":"Marques","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Coimbra"}]}],"member":"276","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"key":"bib1-20250802","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","year":"2018","journal-title":"JAMA"},{"key":"bib2-20250802","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"bib3-20250802","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"bib9-20250802","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.39463","article-title":"Decernotinib: a next-generation jakinib","volume":"68","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"bib10-20250802","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s40265-019-01131-y","article-title":"Peficitinib: first global approval","volume":"79","year":"2019","journal-title":"Drugs"},{"key":"bib11-20250802","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","article-title":"Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"bib12-20250802","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/annrheumdis-2019-216852","article-title":"Infections in baricitinib clinical trials for patients with active rheumatoid arthritis","volume":"79","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"bib13-20250802","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"bib15-20250802","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","year":"2015","journal-title":"Ann Intern Med"},{"key":"bib16-20250802","doi-asserted-by":"crossref","first-page":"e041420","DOI":"10.1136\/bmjopen-2020-041420","article-title":"Risk of infections and cardiovascular and venous thromboembolic events associated with JAK inhibitors in rheumatoid arthritis: protocols of two systematic reviews and network meta-analyses","volume":"10","year":"2020","journal-title":"BMJ Open"},{"key":"bib17-20250802","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European league against rheumatism collaborative initiative","volume":"69","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"bib18-20250802","first-page":"l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","year":"2019","journal-title":"BMJ"},{"key":"bib19-20250802","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"Network meta-analysis","volume":"15","year":"2015","journal-title":"Stata J"},{"key":"bib20-20250802","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/1536867X1501500402","article-title":"Visualizing assumptions and results in network meta-analysis: The network graphs package","volume":"15","year":"2015","journal-title":"Stata J"},{"key":"bib21-20250802","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"bib22-20250802","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","article-title":"The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment","volume":"52","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"bib23-20250802","doi-asserted-by":"crossref","first-page":"e000935","DOI":"10.1136\/rmdopen-2019-000935","article-title":"Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study","volume":"5","year":"2019","journal-title":"RMD Open"},{"key":"bib24-20250802","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"79","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"bib25-20250802","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"bib26-20250802","first-page":"79","article-title":"Clinical use of anti-TNF therapy and increased risk of infections","volume":"5","year":"2013","journal-title":"Drug Healthc Patient Saf"},{"key":"bib27-20250802","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","year":"2006","journal-title":"JAMA"},{"key":"bib28-20250802","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/acr2.11064","article-title":"Risk of serious infection in patients with rheumatoid arthritis treated with biologic versus nonbiologic disease-modifying antirheumatic drugs","volume":"1","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"bib29-20250802","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1016\/S2665-9913(19)30137-7","article-title":"Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"2","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"bib30-20250802","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response","volume":"78","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"bib31-20250802","first-page":"318","article-title":"The mechanism of action of tofacitinib\u2014an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"bib32-20250802","doi-asserted-by":"crossref","first-page":"181","DOI":"10.55563\/clinexprheumatol\/n6zc67","article-title":"One year in review 2020: novelties in the treatment of rheumatoid arthritis","volume":"38","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"bib33-20250802","first-page":"F1000","article-title":"Natural killer cells in herpesvirus infections","volume":"6","year":"2017","journal-title":"F1000Res"},{"key":"bib34-20250802","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/art.40186","article-title":"Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective JAK-1 inhibitor, after short-term treatment of rheumatoid arthritis: results of two randomized phase IIa trials","volume":"69","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"bib35-20250802","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","year":"2014","journal-title":"J Med Chem"},{"key":"bib36-20250802","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0092-8674(00)81166-6","article-title":"Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses","volume":"93","year":"1998","journal-title":"Cell"},{"key":"bib37-20250802","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.rdc.2015.08.004","article-title":"Infection risk and safety of corticosteroid use","volume":"42","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"bib38-20250802","doi-asserted-by":"crossref","first-page":"e000536","DOI":"10.1136\/rmdopen-2017-000536","article-title":"Glucocorticoids in rheumatoid arthritis: current status and future studies","volume":"6","year":"2020","journal-title":"RMD Open"},{"key":"bib39-20250802","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/rheumatology\/key256","article-title":"Clinical efficacy of new JAK inhibitors under development. Just more of the same?","volume":"58","year":"2019","journal-title":"Rheumatology (Oxford)"}],"container-title":["JCR: Journal of Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RHU.0000000000001749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T20:13:13Z","timestamp":1754165593000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RHU.0000000000001749"}},"subtitle":["A Systematic Review and Network Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rhu.0000000000001749","relation":{},"ISSN":["1536-7355","1076-1608"],"issn-type":[{"value":"1536-7355","type":"electronic"},{"value":"1076-1608","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,26]]}}}